Croitoru A, Dinu I, Herlea V, Becheanu G, Grasu M, Lupescu I
Acta Endocrinol (Buchar). 2020; 15(3):390-397.
PMID: 32010361
PMC: 6992400.
DOI: 10.4183/aeb.2019.390.
Thomas K, Voros B, Meadows-Taylor M, Smeltzer M, Griffin R, Boudreaux J
Cancers (Basel). 2020; 12(1).
PMID: 31947598
PMC: 7017154.
DOI: 10.3390/cancers12010206.
Chen M, Chou W, Hsiao C, Jiang S, Tsai H, Liu Y
Oncologist. 2019; 25(5):e782-e788.
PMID: 31852810
PMC: 7216444.
DOI: 10.1634/theoncologist.2019-0490.
Zhu X, Jing H, Yao T
Medicine (Baltimore). 2019; 98(30):e16638.
PMID: 31348317
PMC: 6709248.
DOI: 10.1097/MD.0000000000016638.
Thomas K, Voros B, Boudreaux J, Thiagarajan R, Woltering E, Ramirez R
Oncologist. 2019; 24(8):1076-1088.
PMID: 30635447
PMC: 6693730.
DOI: 10.1634/theoncologist.2018-0604.
Grading of Neuroendocrine Carcinomas: Correlation of Ga-PET/CT Scan with Tissue Biomarkers.
Liverani C, Bongiovanni A, Mercatali L, Foca F, Pieri F, De Vita A
Dis Markers. 2019; 2018:6878409.
PMID: 30627226
PMC: 6304840.
DOI: 10.1155/2018/6878409.
Neuroendocrine neoplasms - still a challenge despite major advances in clinical care with the development of specialized guidelines.
Petersenn S, Koch C
Rev Endocr Metab Disord. 2018; 18(4):373-378.
PMID: 29480376
DOI: 10.1007/s11154-018-9442-7.
Loss of succinate dehydrogenase subunit B (SDHB) as a prognostic factor in advanced ileal well-differentiated neuroendocrine tumors.
Milione M, Maisonneuve P, Pellegrinelli A, Pusceddu S, Centonze G, Dominoni F
Endocrine. 2016; 57(3):512-517.
PMID: 27905048
DOI: 10.1007/s12020-016-1180-6.
Small bowel neuroendocrine tumors: From pathophysiology to clinical approach.
Xavier S, Rosa B, Cotter J
World J Gastrointest Pathophysiol. 2016; 7(1):117-24.
PMID: 26909234
PMC: 4753177.
DOI: 10.4291/wjgp.v7.i1.117.
[Surgical approach of gastroduodenal neuroendocrine neoplasms].
Fendrich V, Bartsch D
Chirurg. 2016; 87(4):280-7.
PMID: 26779647
DOI: 10.1007/s00104-015-0138-1.
First-line chemotherapy in patients with metastatic gastroenteropancreatic neuroendocrine carcinoma.
Bongiovanni A, Riva N, Ricci M, Liverani C, La Manna F, De Vita A
Onco Targets Ther. 2015; 8:3613-9.
PMID: 26664145
PMC: 4671803.
DOI: 10.2147/OTT.S91971.
Inverse expression of somatostatin and CXCR4 chemokine receptors in gastroenteropancreatic neuroendocrine neoplasms of different malignancy.
Kaemmerer D, Trager T, Hoffmeister M, Sipos B, Hommann M, Sanger J
Oncotarget. 2015; 6(29):27566-79.
PMID: 26259237
PMC: 4695009.
DOI: 10.18632/oncotarget.4491.
High-dose lanreotide in the treatment of poorly differentiated pancreatic neuroendocrine carcinoma: a case report.
Van Fraeyenhove F, Meireson N, Terriere L, Willemsen P, Kunnen J, Mattelaer C
Case Rep Oncol. 2014; 7(1):155-63.
PMID: 24707264
PMC: 3975754.
DOI: 10.1159/000360732.
Duodenal adenocarcinoma following a neuroendocrine tumor in the duodenum.
Kim B, Huh J, Kim Y, Chung M, Park J, Song S
Korean J Intern Med. 2014; 29(1):96-100.
PMID: 24574838
PMC: 3932400.
DOI: 10.3904/kjim.2014.29.1.96.
New model for gastroenteropancreatic large-cell neuroendocrine carcinoma: establishment of two clinically relevant cell lines.
Krieg A, Mersch S, Boeck I, Dizdar L, Weihe E, Hilal Z
PLoS One. 2014; 9(2):e88713.
PMID: 24551139
PMC: 3925161.
DOI: 10.1371/journal.pone.0088713.
Succinate dehydrogenase B subunit immunohistochemical expression predicts aggressiveness in well differentiated neuroendocrine tumors of the ileum.
Milione M, Pusceddu S, Gasparini P, Melotti F, Maisonneuve P, Mazzaferro V
Cancers (Basel). 2013; 4(3):808-20.
PMID: 24213468
PMC: 3712706.
DOI: 10.3390/cancers4030808.
Contemporary methods of therapy and follow-up of neuroendocrine tumours of the gastrointestinal tract and the pancreas.
Gut P, Fischbach J, Kaminski G, Ruchala M
Contemp Oncol (Pozn). 2013; 16(5):371-5.
PMID: 23788913
PMC: 3687448.
DOI: 10.5114/wo.2012.31764.
Treatment of malignant pancreatic neuroendocrine neoplasms: middle-term (2-year) outcomes of a prospective observational multicentre study.
Zerbi A, Capitanio V, Boninsegna L, Delle Fave G, Pasquali C, Rindi G
HPB (Oxford). 2013; 15(12):935-43.
PMID: 23472667
PMC: 3843611.
DOI: 10.1111/hpb.12065.
Pharmacotherapy of Zollinger-Ellison syndrome.
Ito T, Igarashi H, Uehara H, Jensen R
Expert Opin Pharmacother. 2013; 14(3):307-21.
PMID: 23363383
PMC: 3580316.
DOI: 10.1517/14656566.2013.767332.
Surgical treatment of sporadic pancreatic neuroendocrine tumors: a state of the art review.
Haugvik S, Labori K, Edwin B, Mathisen O, Gladhaug I
ScientificWorldJournal. 2013; 2012:357475.
PMID: 23304085
PMC: 3523601.
DOI: 10.1100/2012/357475.
